TAK 442

Known as: TAK-442, TAK442 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2013
01220092013

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
TAK-442 is an oral direct factor Xa inhibitor. We sought to determine the dose-dependent effect of TAK-442 on major bleeding when… (More)
Is this relevant?
Review
2012
Review
2012
Thrombosis plays a key role in the pathophysiology of acute coronary syndromes (ACS). The management of patients with ACS… (More)
Is this relevant?
2011
2011
Endothelial damage triggers platelet adhesion and platelet-associated prothrombinase formation at the point of injury, resulting… (More)
Is this relevant?
2010
2010
This multicentre dose-finding study compared TAK-442, an oral factor Xa inhibitor, with enoxaparin for thromboprophylaxis after… (More)
Is this relevant?
2010
2010
Coagulation enzyme factor Xa (FXa) is a particularly promising target for the development of new anticoagulant agents. We… (More)
Is this relevant?
2010
2010
The anticoagulant and antithrombotic profiles of TAK-442, a direct factor Xa (FXa) inhibitor, were investigated. TAK-442 showed… (More)
Is this relevant?
2010
2010
INTRODUCTION Activated platelets facilitate blood coagulation by providing factor V and a procoagulant surface for prothrombinase… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
2010
2010
Thrombin amplifies the blood coagulation via factor V (FV)-mediated positive feedback loop. We hypothesised that factor Xa (FXa… (More)
Is this relevant?
2010
2010
Venous thromboembolism is the third leading cause of cardiovascular death, after myocardial infarction and stroke.1 Total hip or… (More)
Is this relevant?
Review
2009
Review
2009
Anticoagulation is recommended for prophylaxis and treatment of venous thromboembolism (VTE) (deep vein thrombosis and pulmonary… (More)
Is this relevant?